Condition: Moderate-to-severe Chronic Noncancer Pain · Sponsor: Egalet Ltd
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Site 334 | Huntsville, Alabama, United States | — |
| Site 328 | Tucson, Arizona, United States | — |
| Site 332 | Jacksonville, Florida, United States | — |
| Site 340 | Miami Gardens, Florida, United States | — |
| Site 320 | Plantation, Florida, United States | — |
| Site 302 | Tampa, Florida, United States | — |
| Site 315 | Tampa, Florida, United States | — |
| Site 310 | Winter Haven, Florida, United States | — |
| Site 316 | Dawsonville, Georgia, United States | — |
| Site 311 | Marietta, Georgia, United States | — |
| Site 336 | Bloomington, Illinois, United States | — |
| Site 345 | Blue Island, Illinois, United States | — |
+ 27 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02603705